US Patent Issued to Euclises Pharmaceuticals on Feb. 10 for "Combination of a chromene compound and a second active agent" (Missouri, Pennsylvania Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,544,356, issued on Feb. 10, was assigned to Euclises Pharmaceuticals Inc. (Saint Louis, Mo.).

"Combination of a chromene compound and a second active agent" was invented by John J. Talley (Saint Louis, Mo.), Bobby W. Sandage Jr. (Creve Coeur, Mo.) and Eduardo J. Martinez (Bryn Mawr, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provide a combination of a chromene compound having the structure of Formula (I), or pharmaceutically acceptable salts, and a second compound that can be selected from a PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, OX-40 agonist, CD137 agonist, LAG-3 inhibitor, IDO inhibitor, bi-specific protein,...